WO2004087207A3 - Method for inducing apoptosis and aneuploidy regression in cancer cells - Google Patents

Method for inducing apoptosis and aneuploidy regression in cancer cells Download PDF

Info

Publication number
WO2004087207A3
WO2004087207A3 PCT/US2004/009270 US2004009270W WO2004087207A3 WO 2004087207 A3 WO2004087207 A3 WO 2004087207A3 US 2004009270 W US2004009270 W US 2004009270W WO 2004087207 A3 WO2004087207 A3 WO 2004087207A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer cells
regression
egfr
erbb2
inhibitors
Prior art date
Application number
PCT/US2004/009270
Other languages
French (fr)
Other versions
WO2004087207A2 (en
Inventor
Oezge Alper
Original Assignee
Univ Georgetown
Oezge Alper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown, Oezge Alper filed Critical Univ Georgetown
Publication of WO2004087207A2 publication Critical patent/WO2004087207A2/en
Publication of WO2004087207A3 publication Critical patent/WO2004087207A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Abstract

The instant invention provides methods and reagents for treating cancer, through inducing apoptosis and/or inducing aneuploidy regression and/or differentiation in cancer cells. The methods of the invention comprise administering one or more inhibitors to simultaneously block signaling through the EGFR and the c-erbB2 receptor, such as simultaneously suppress phosphorylated EGFR and erbB2. The inhibitors may include anti-sense RNA of the receptors, short fragments of dsRNA corresponding to segments of the EGFR or c-erbB2 mRNA, DNA encoding such RNAs (preferably on a vector that can be delivered to target cancer cells), function-antagonizing antibodies against the receptors, or small peptide inhibitors that block receptor activation.
PCT/US2004/009270 2003-03-27 2004-03-26 Method for inducing apoptosis and aneuploidy regression in cancer cells WO2004087207A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45814603P 2003-03-27 2003-03-27
US60/458,146 2003-03-27

Publications (2)

Publication Number Publication Date
WO2004087207A2 WO2004087207A2 (en) 2004-10-14
WO2004087207A3 true WO2004087207A3 (en) 2005-01-20

Family

ID=33131757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009270 WO2004087207A2 (en) 2003-03-27 2004-03-26 Method for inducing apoptosis and aneuploidy regression in cancer cells

Country Status (1)

Country Link
WO (1) WO2004087207A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2006078307A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
US20060188509A1 (en) 2005-02-23 2006-08-24 Genentech, Inc. Extending time to disease progression or survival in cancer patients
PE20090681A1 (en) 2007-03-02 2009-06-10 Genentech Inc PREDICTION OF RESPONSE TO A HER INHIBITOR
ES2583377T3 (en) 2007-06-08 2016-09-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2170404A4 (en) * 2007-06-22 2011-01-19 Intradigm Corp Compositions comprising human egfr-sirna and methods of use
CN101492690B (en) * 2008-03-04 2011-07-27 天津医科大学总医院 Plasmid vector of polygene combined gene therapy based on RNAi technique
TW201438739A (en) 2009-03-20 2014-10-16 Genentech Inc Anti-HER antibodies
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US9427458B2 (en) 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
RU2013114360A (en) 2010-08-31 2014-10-10 Дженентек, Инк. BIOMARKERS AND TREATMENT METHODS
RU2014126098A (en) 2011-11-30 2016-01-27 Дженентек, Инк. Mutations of ErbB3 in Cancer
SG11201406079TA (en) 2012-03-27 2014-10-30 Genentech Inc Diagnosis and treatments relating to her3 inhibitors
KR20160137599A (en) 2014-03-24 2016-11-30 제넨테크, 인크. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
KR20190140952A (en) 2017-04-24 2019-12-20 제넨테크, 인크. ERBB2 / HER2 mutations in transmembrane and proximal membrane domains

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ALPER OZGE ET AL: "Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: Crosstalk with tyrosine kinase signaling pathway", ONCOGENE, vol. 18, no. 35, 2 September 1999 (1999-09-02), pages 4999 - 5004, XP002302017, ISSN: 0950-9232 *
ARTEAGA CARLOS: "Targeting HER1/EGFR: a molecular approach to cancer therapy.", SEMINARS IN ONCOLOGY. JUN 2003, vol. 30, no. 3 Suppl 7, June 2003 (2003-06-01), pages 3 - 14, XP009038621, ISSN: 0093-7754 *
BRADER KEVIN R ET AL: "Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line", ONCOLOGY REPORTS, vol. 5, no. 5, September 1998 (1998-09-01), pages 1269 - 1274, XP009038810, ISSN: 1021-335X *
FAN W H ET AL: "EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human breast cancer MDA-MB-231 cells.", CELL RESEARCH. MAR 1998, vol. 8, no. 1, March 1998 (1998-03-01), pages 63 - 71, XP009038811, ISSN: 1001-0602 *
MOULDER S L ET AL: "EPIDERMAL GROWTH FACTOR RECEPTOR (HER1) TYROSINE KINASE INHIBITOR ZD1839 (IRESSA) INHIBITS HER2/NEU (ERB2)-OVEREXPRESSING BREAST CANCER CELLS IN VITRO AND IN VIVO", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 24, 15 December 2001 (2001-12-15), pages 8887 - 8895, XP001056506, ISSN: 0008-5472 *
MOULDER STACY L ET AL: "A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).", CLINICAL BREAST CANCER. JUN 2003, vol. 4, no. 2, June 2003 (2003-06-01), pages 142 - 145, XP009038641, ISSN: 1526-8209 *
NORMANNO N ET AL: "Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.", ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO. JAN 2002, vol. 13, no. 1, January 2002 (2002-01-01), pages 65 - 72, XP002302015, ISSN: 0923-7534 *
PACK SVETLANA D ET AL: "Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line.", CANCER RESEARCH, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 789 - 794, XP002302018, ISSN: 0008-5472 *
ROH H ET AL: "HER2/neu antisense targeting of human breast carcinoma", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 19, 2000, pages 6138 - 6143, XP002974518, ISSN: 0950-9232 *
ROH HAERI ET AL: "Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu", CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 560 - 565, XP002302906, ISSN: 0008-5472 *
SARTOR C I: "Epidermal growth factor family receptors and inhibitors: Radiation response modulators", SEMINARS IN RADIATION ONCOLOGY 2003 UNITED STATES, vol. 13, no. 1, 2003, pages 22 - 30, XP009038626, ISSN: 1053-4296 *
XIA WENLE ET AL: "Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways", ONCOGENE, vol. 21, no. 41, 12 September 2002 (2002-09-12), pages 6255 - 6263, XP002302016, ISSN: 0950-9232 *
YE D ET AL: "AUGMENTATION OF A HUMANIZED ANTI-HER2 MAB 4D5 INDUCED GROWTH INHIBITION BY A HUMAN-MOUSE CHIMERIC ANTI-EGF RECEPTOR MAB C225", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 18, no. 3, 21 January 1999 (1999-01-21), pages 731 - 738, XP001096335, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2004087207A2 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2004087207A3 (en) Method for inducing apoptosis and aneuploidy regression in cancer cells
WO2006060419A3 (en) Biomarkers for pre-selection of patients for anti-igf1r therapy
WO2005116236A3 (en) Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
UA94576C2 (en) Isolated antibody that binds to igf-1r, composition and methods relating to anti-igf-1 receptor antibodies
RS52593B (en) Treatment of conditions involving demyelination
WO2005005462A3 (en) Blys antagonists and uses thereof
WO1999022773A3 (en) Sequences for targeting metastatic cells
ATE508188T1 (en) OLIGONUCLEOTIDE COMPOSITIONS WITH IMPROVED EFFECTIVENESS
AU2002343792A1 (en) siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
WO2007044468A3 (en) Method to treat flavivirus infection with sirna
WO2007117657A3 (en) Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
KR20160033251A (en) Organic compositions to treat hsf1-related diseases
WO2020198509A3 (en) Modified oligonucleotides with increased stability
EP1715896A4 (en) Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
Gabriele et al. Angiotensin II Type 1 receptor knockdown impairs interleukin‐1β‐Induced cytokines in human periodontal fibroblasts
WO2006017318A3 (en) Methods for treating cancer using agents that inhibit wnt16 signaling
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
WO2004070025A3 (en) Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
WO2008067305A3 (en) Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
MXPA05006034A (en) Replication protein.
WO2004046182A3 (en) Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases
WO2007033298A3 (en) Hydrolase and methods for its use
WO2006060335A3 (en) Cellular signaling pathway based assays, reagents and kits

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase